Binder effectiveness of microcapsules applied onto cotton fabrics during laundry

[EN] Microcapsules can be added to fabric in industrial processes; however, they have not been widely spread among industrial companies. In this study, we suggest the possibility of reloading microcapsules onto a fabric while clothes are washed. The effectiveness of different resins when microcapsules are applied in washing machine during domestic laundry process has been studied. Microcapsules containing lavender fragrance and melamine formaldehyde shell were adhered to the fabric by means of one acrylic acid as a resin (RES) or some cross-linking agents, such as butanetetracarboxylic acid or succinic acid (SUC). In order to evaluate their behaviour, some laundering or ironing tests were conducted according to international standards (ISO). Every sample from the laboratory was studied with scanning electron microscopy and with a particle size counter. As a result, we could observe which was the most suitable auxiliary used to bind microcapsules to fabric, and conclude that the conditions in which we obtained the application with SUC as binder and cured at 150 °C for 2 min show the optimal results. It was demonstrated that domestic laundry is a suitable process to incorporate microcapsules to garments.Authors gratefully acknowledge the financial support received by this research project from the Spanish government in the programme 'Plan Nacional 2008-2011' reference Mat 2009-14210-C02-01.Bonet Aracil, MA.; Bou Belda, E.; Monllor Pérez, P.; Gisbert; Jaime (2016). Binder effectiveness of microcapsules applied onto cotton fabrics during laundry. The Journal of the Textile Institute. 107(3):300-306. https://doi.org/10.1080/00405000.2015.1029808S300306107

Mosquito Repellency of Polyester Nets Treated with Cyclodextrin/Repellent Complexes

Fabric treatments with β-Cyclodextrins (β-CD) have been studied for different applications as nanotechnologycal approaches to achieve functional textiles. In particular, repellents and insecticides have been incorporated in β-CD treated textiles to prolong their release. In this case, Citriodiol®, a naturally derived mosquito repellent, was incorporated to β-CD treated polyester (PET) nets. Two methods for citriodiol inclusion were studied; i) pipette dripping or ii) impregnation of fabric in a plastic bag, in order to increase the repellent activity of PET textile substrates. Release profiles were analyzed by gas chromatography and repellency was monitored by in vivo assays with Aedes aegypti mosquitoes. Long lasting and reloadable mosquito repellent nets could be achieved by treating PET knits with citriodiol/β-CD complexes.Centro de Estudios Parasitológicos y de Vectore

Mosquito Repellency of Polyester Nets Treated with Cyclodextrin/Repellent Complexes

Fabric treatments with β-Cyclodextrins (β-CD) have been studied for different applications as nanotechnologycal approaches to achieve functional textiles. In particular, repellents and insecticides have been incorporated in β-CD treated textiles to prolong their release. In this case, Citriodiol®, a naturally derived mosquito repellent, was incorporated to β-CD treated polyester (PET) nets. Two methods for citriodiol inclusion were studied; i) pipette dripping or ii) impregnation of fabric in a plastic bag, in order to increase the repellent activity of PET textile substrates. Release profiles were analyzed by gas chromatography and repellency was monitored by in vivo assays with Aedes aegypti mosquitoes. Long lasting and reloadable mosquito repellent nets could be achieved by treating PET knits with citriodiol/β-CD complexes.Centro de Estudios Parasitológicos y de Vectore

Cost-effectiveness of implementing a digital psychosocial intervention for patients with psychotic spectrum disorders in low- and middle-income countries in Southeast Europe: Economic evaluation alongside a cluster randomised trial

BACKGROUND: DIALOG+ is a digital psychosocial intervention aimed at making routine meetings between patients and clinicians therapeutically effective. This study aimed to evaluate the cost-effectiveness of implementing DIALOG+ treatment for patients with psychotic disorders in five low- and middle-income countries in Southeast Europe alongside a cluster randomised trial. METHODS: Resource use and quality of life data were collected alongside the multi-country cluster randomised trial of 468 participants with psychotic disorders. Due to COVID-19 interruptions of the trial’s original 12-month intervention period, adjusted costs and quality-adjusted life years (QALYs) were estimated at the participant level using a mixed-effects model over the first 6 months only. We estimated the incremental cost-effectiveness ratio (ICER) with uncertainty presented using a cost-effectiveness plane and a cost-effectiveness acceptability curve. Seven sensitivity analyses were conducted to check the robustness of the findings. RESULTS: The average cost of delivering DIALOG+ was €91.11 per participant. DIALOG+ was associated with an incremental health gain of 0.0032 QALYs (95% CI –0.0015, 0.0079), incremental costs of €84.17 (95% CI –8.18, 176.52), and an estimated ICER of €26,347.61. The probability of DIALOG+ being cost-effective against three times the weighted gross domestic product (GDP) per capita for the five participating countries was 18.9%. CONCLUSION: Evidence from the cost-effectiveness analyses in this study suggested that DIALOG+ involved relatively low costs. However, it is not likely to be cost-effective in the five participating countries compared with standard care against a willingness-to-pay threshold of three times the weighted GDP per capita per QALY gained

Essential to increase the use of generics in Europe to maintain comprehensive health care?

INTRODUCTION: Reforms have been introduced across Europe to increase prescribing efficiency with existing drugs. These include measures to lower prices of generics as well as increase their prescribing versus originators and patented products in a class or related class. This is essential to maintain comprehensive health care in Europe given continued pressures. The alternative is insufficient funds for new innovative drugs and increasing drug volumes with ageing populations. OBJECTIVE: To review the influence of measures and initiatives to increase the prescribing and dispensing of generics at low prices on ambulatory care prescribing efficiency. In view of this, provide guidance as authorities strive to introduce further reforms to meet their goals. METHODOLOGY: A narrative review of published papers combined with case histories. RESULTS: The different supply- and demand-side measures have reduced generic prices to as low as 2% to 3% of pre-patent loss prices in some cases as well as appreciably enhanced their utilisation. As a result, prescribing efficiency has increased without compromising care. In some cases, the reforms have led to expenditure actually falling despite appreciably increased volumes. CONCLUSIONS: Increasing use of generics at low prices will help maintain the European ideals of comprehensive and equitable health care. However, countries will continually need to learn from each other

The Implementation of Managed Entry Agreements in Central and Eastern Europe : Findings and Implications

Funding Information: In Bosnia and Herzegovina, both The Federation of Bosnia and Herzegovina and the Republic of Srpska, also have special funds and budgets in place for the financing of expensive medicines, which are innovative and under patent. Similar earmarked funds are available in Scotland (the New Medicines Fund funded by the Pharmaceutical Price Regulation Scheme [PPRS] rebates) [35] and England (the Cancer Drugs Fund) [36]. However, support for such earmarked funds is mixed. While they facilitate access, critics raised issues about fairness towards other disease areas and patient groups that are not eligible for special funding [3, 39]. Further, the views of a Patient and Clinician Engagement meeting in Scotland [37] and the end-of-life criteria in England [38] offer opportunities for special considerations affecting medicines for end-of-life and very rare conditions to be taken into account in the health technology assessment process. Funding Information: The authors would like to acknowledge Dr. Jan Jones from the Scottish Medicines Consortium, Scotland, for contributing to the discussion with information on Scotland, Drs. Lyudmila Bezmelnitsyna and Anastasia Isaeva for contributing to data collection in Russia and Dr. Kate?ina Podrazilov? from SZP ?R for providing information on the Czech Republic. Alessandra Ferrario was a Research Officer at the LSE Health at the time this research was conducted. She is now a postdoctoral Research Fellow at the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, USA. Email: [email protected] No sources of funding were used for this study. The authors declare they have no conflicts of interest. However, Di?na Ar?ja, Maria Dimitrova, Jurij F?rst, Ieva Grei?i?t?-Kuprijanov, Iris Hoxha, Arianit Jakupi, Erki Laidm?e, Vanda Markovic-Pekovic, Dmitry Meshkov, Guenka Petrova, Maciej Pomorski and Patricia Vella Bonanno work directly for national health authorities or are advisers to them. Alessandra Ferrario, Tomasz Bochenek, Ileana Mardare, Dominik Tomek, Luka Voncina, Alan Haycox, Panos Kanavos,?Olga L?blov?, and Brian Godman are academics and independent researchers also working with national and regional health authorities and others to improve the quality and efficiency of prescribing, and Tarik Catic, D?vid Dank?,and Tanja Novakovic are involved with pharmaceutical, pharmacoeconomics and outcomes research groups in their countries. Olga L?blov? has also carried out remunerated consultancy activities for A&R Partners, Baxter AG and Instytut Arcana and Ileana Mardare has signed a consulting contract with Ewopharma A.G. Romania. The content of the paper and the conclusions are those of each author and may not necessarily reflect those of any organisation that employs them. Publisher Copyright: © 2017, The Author(s).Background: Managed entry agreements (MEAs) are a set of instruments to facilitate access to new medicines. This study surveyed the implementation of MEAs in Central and Eastern Europe (CEE) where limited comparative information is currently available. Method: We conducted a survey on the implementation of MEAs in CEE between January and March 2017. Results: Sixteen countries participated in this study. Across five countries with available data on the number of different MEA instruments implemented, the most common MEAs implemented were confidential discounts (n = 495, 73%), followed by paybacks (n = 92, 14%), price-volume agreements (n = 37, 5%), free doses (n = 25, 4%), bundle and other agreements (n = 19, 3%), and payment by result (n = 10, >1%). Across seven countries with data on MEAs by therapeutic group, the highest number of brand names associated with one or more MEA instruments belonged to the Anatomical Therapeutic Chemical (ATC)-L group, antineoplastic and immunomodulating agents (n = 201, 31%). The second most frequent therapeutic group for MEA implementation was ATC-A, alimentary tract and metabolism (n = 87, 13%), followed by medicines for neurological conditions (n = 83, 13%). Conclusions: Experience in implementing MEAs varied substantially across the region and there is considerable scope for greater transparency, sharing experiences and mutual learning. European citizens, authorities and industry should ask themselves whether, within publicly funded health systems, confidential discounts can still be tolerated, particularly when it is not clear which country and party they are really benefiting. Furthermore, if MEAs are to improve access, countries should establish clear objectives for their implementation and a monitoring framework to measure their performance, as well as the burden of implementation.publishersversionPeer reviewe

To which countries do European psychiatric trainees want to move to and why?

publisher: Elsevier articletitle: To which countries do European psychiatric trainees want to move to and why? journaltitle: European Psychiatry articlelink: http://dx.doi.org/10.1016/j.eurpsy.2017.06.010 content_type: article copyright: © 2017 Elsevier Masson SAS. All rights reserved.publisher: Elsevier articletitle: To which countries do European psychiatric trainees want to move to and why? journaltitle: European Psychiatry articlelink: http://dx.doi.org/10.1016/j.eurpsy.2017.06.010 content_type: article copyright: © 2017 Elsevier Masson SAS. All rights reserved.BACKGROUND: There is a shortage of psychiatrists worldwide. Within Europe, psychiatric trainees can move between countries, which increases the problem in some countries and alleviates it in others. However, little is known about the reasons psychiatric trainees move to another country. METHODS: Survey of psychiatric trainees in 33 European countries, exploring how frequently psychiatric trainees have migrated or want to migrate, their reasons to stay and leave the country, and the countries where they come from and where they move to. A 61-item self-report questionnaire was developed, covering questions about their demographics, experiences of short-term mobility (from 3 months up to 1 year), experiences of long-term migration (of more than 1 year) and their attitudes towards migration. RESULTS: A total of 2281 psychiatric trainees in Europe participated in the survey, of which 72.0% have 'ever' considered to move to a different country in their future, 53.5% were considering it 'now', at the time of the survey, and 13.3% had already moved country. For these immigrant trainees, academic was the main reason they gave to move from their country of origin. For all trainees, the overall main reason for which they would leave was financial (34.4%), especially in those with lower (2500€) incomes, personal reasons were paramount (44.5%). CONCLUSIONS: A high number of psychiatric trainees considered moving to another country, and their motivation largely reflects the substantial salary differences. These findings suggest tackling financial conditions and academic opportunities